Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.

There is no vaccine for T.Gondii and hypersensitivity and toxicity limit the use of the few available medicines: When are pharmaceutical companies going to take an interest ? A compound likely exists in the millions already synthesised. This could be of much much more use than novel neuroleptics. Risk factors: Schizophrenia Kegg pathways Schizophrenia